Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

linical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director,

Corporate Communications & Investor Relations

EntreMed, Inc.

240-864-2643

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

December 31,

2007 2006

Total revenues $3,875,392 $3,871,173

Research and development $5,650,152 $7,857,677

General and administrative $1,978,982 $2,136,764

Net loss $(3,767,496) $(5,627,632)

Dividend on Series A convertible

preferred stock $(251,250) $(251,250)

Net loss attributable to common

shareholders $(4,018,746) $(5,878,882)

Net loss per share attributable to

common shareholders (basic and diluted) $(0.05) $(0.08)

Weighted average number of

shares outstanding (basic and diluted) 84,362,710 74,606,821

Twelve Months Ended

December 31,

2007 2006

Total revenues $7,395,651 $6,894,358

Research and development $23,739,392 $21,671,117

General and administrative $7,386
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email: